Klotho Neurosciences, Inc. (KLTO) - Total Liabilities
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has total liabilities worth $145.89K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Klotho Neurosciences, Inc. (KLTO) net asset momentum to track the company's year-over-year net asset growth rate.
Klotho Neurosciences, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Klotho Neurosciences, Inc. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Klotho Neurosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SuperCom Ltd
F:50S
|
Germany | €28.23 Million |
|
Dinamik Isi Makina Yalitim Malzemeleri Sanayi ve Ticaret AS
IS:DNISI
|
Turkey | TL343.85 Million |
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
USA | $7.83 Million |
|
Polychem Indonesia Tbk
JK:ADMG
|
Indonesia | Rp44.23 Million |
|
Poujoulat S.A.
PA:ALPJT
|
France | €215.04 Million |
|
Optivision Technology
TWO:3666
|
Taiwan | NT$387.67 Million |
|
Genie Music Corporation
KQ:043610
|
Korea | ₩115.36 Billion |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
Korea | ₩18.93 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Klotho Neurosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KLTO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 83.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Klotho Neurosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual total liabilities of Klotho Neurosciences, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.27 Million | -21.53% |
| 2023-12-31 | $1.62 Million | +19.17% |
| 2022-12-31 | $1.36 Million | +8887.60% |
| 2021-12-31 | $15.13K | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more